☆ 4.8 Letter

Ivosidenib and Azacitidine in IDH1-Mutated AML

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Impact of Venetoclax and Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia and IDH1/2 Mutations

Daniel A. Pollyea et al.

Summary: The combination therapy of venetoclax and azacitidine shows high efficacy and safety in patients with IDH1/2-mutant acute myeloid leukemia (AML), leading to improved overall survival.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Medicine, General & Internal

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Pau Montesinos et al.

Summary: This study demonstrated that the combination therapy of oral ivosidenib and azacitidine showed better event-free survival and longer overall survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials A Systematic Review

Ghulam Rehman Mohyuddin et al.

Summary: This systematic review found that less than half of multiple myeloma randomized clinical trials reported postprotocol therapies, with a low proportion of patients receiving these therapies, often not meeting the standard of care. Reporting guidelines for postprotocol therapies are urgently needed to improve the reporting quality in ongoing and future trials.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal